# PD_Lab_book


## Objective 1
###### Learning cell culture basics
###### SRB cytotoxicity assays with crizotinib
Aim: 3 or more consistent concentration/cell viability curves<br>
[Results](Objective_summaries/O1_crizotinib.md)

## Objective 2
###### SRB cytotoxicity assay with selumetinib (MEK inhibitor)
Concentrations via Nensi<br>
Aim: 3 or more consistent concentration/cell viability curves<br>
[Results](Objective_summaries/O2_selumetinib.md)

## Objective 3
###### SRB cytotoxicity assay with crizotinib and selumetinib
Concentrations will depend of crizotinib and selumetinib IC50 values<br>
Aim: 3 or more consistent concentration/cell viability curves and learn combination drug data analysis\
[Results](Objective_summaries/O3_crizotinib_selumetinib.md)

## Objective 4
###### SRB cytotoxicity assay with ABT-737
Aim: 3 or more consistent concentration/cell viability curves\
[Results](Objective_summaries/O4_ABT-737.md)

## Objective 5
###### SRB cytotoxicity assay with ABT-737 and crizotinib<br>
Aim: 3 or more consistent concentration/cell viability curves\
[Results](Objective_summaries/O5_crizotinib_ABT.md)

## Objective 6
###### SRB cytotoxicity assay with ABT-737, crizotinib and selumetinib<br>
Aim: 3 or more consistent concentration/cell viability curves<br>
[Results](Objective_summaries/O6_crizotinib_selumetinib_ABT.md)

## Objective 7
###### H3122 and CR-H3122 kinase domain sequencing
Aim: Amplify the ALK kinase domain from both H3122 and CR-H3122 and use Sanger sequencing to identify any crizotinib resistance mutations in CR-H3122. <br>
[Summary](Objective_summaries/O7_kinase_domain_sequencing.md)

## Objective 8
###### H3122 and CR-H3122 whole genome sequencing
Aim: Use WGS to compare the H3122 and CR-H3122 cell lines. <br>
[Summary](Objective_summaries/O8_WGS.md)

## Objective 9
###### H3122 ABT-737 Western blots
Aim: Measure the change in cleaved caspase 3 in H3122 cells after exposure to ABT-737. <br> <br>
[Summary](Objective_summaries/O9_ABT_westerns.md)
